Xact Kapitalforvaltning AB lowered its position in Humana Inc (NYSE:HUM) by 14.0% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 22,571 shares of the insurance provider’s stock after selling 3,684 shares during the period. Xact Kapitalforvaltning AB’s holdings in Humana were worth $7,641,000 as of its most recent SEC filing.
Several other large investors have also recently made changes to their positions in the company. Raymond James Trust N.A. raised its position in shares of Humana by 19.8% in the 2nd quarter. Raymond James Trust N.A. now owns 956 shares of the insurance provider’s stock worth $284,000 after acquiring an additional 158 shares in the last quarter. Trust Co increased its position in Humana by 7.7% during the 1st quarter. Trust Co now owns 2,326 shares of the insurance provider’s stock valued at $625,000 after buying an additional 167 shares in the last quarter. Daiwa SB Investments Ltd. increased its position in Humana by 27.9% during the 2nd quarter. Daiwa SB Investments Ltd. now owns 780 shares of the insurance provider’s stock valued at $232,000 after buying an additional 170 shares in the last quarter. Advisor Partners LLC increased its position in Humana by 5.3% during the 2nd quarter. Advisor Partners LLC now owns 3,604 shares of the insurance provider’s stock valued at $1,073,000 after buying an additional 180 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. increased its position in Humana by 1.7% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 11,901 shares of the insurance provider’s stock valued at $3,541,000 after buying an additional 197 shares in the last quarter. 92.99% of the stock is owned by hedge funds and other institutional investors.
Shares of HUM opened at $318.25 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. Humana Inc has a 12 month low of $231.90 and a 12 month high of $341.30. The firm has a market cap of $44.30 billion, a price-to-earnings ratio of 27.18, a price-to-earnings-growth ratio of 1.60 and a beta of 0.97.
The firm also recently announced a quarterly dividend, which was paid on Friday, October 26th. Shareholders of record on Friday, September 28th were paid a dividend of $0.50 per share. The ex-dividend date was Thursday, September 27th. This represents a $2.00 annualized dividend and a yield of 0.63%. Humana’s dividend payout ratio is 17.08%.
In other Humana news, SVP Cynthia H. Zipperle sold 4,886 shares of the stock in a transaction on Friday, August 3rd. The stock was sold at an average price of $321.89, for a total transaction of $1,572,754.54. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Roy A. Beveridge sold 14,306 shares of the stock in a transaction on Monday, August 6th. The shares were sold at an average price of $324.25, for a total value of $4,638,720.50. Following the sale, the insider now owns 15,274 shares in the company, valued at $4,952,594.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 40,284 shares of company stock worth $13,147,715. Company insiders own 0.60% of the company’s stock.
A number of research firms recently weighed in on HUM. Piper Jaffray Companies raised their price objective on Humana from $355.00 to $380.00 and gave the company an “overweight” rating in a research report on Friday, August 24th. Bank of America raised their price objective on Humana from $338.00 to $375.00 and gave the company a “buy” rating in a research report on Thursday, August 2nd. Royal Bank of Canada reaffirmed a “hold” rating and set a $318.00 price objective on shares of Humana in a research report on Thursday, August 2nd. SunTrust Banks raised their price objective on Humana to $380.00 and gave the company a “hold” rating in a research report on Wednesday, September 19th. Finally, Zacks Investment Research lowered Humana from a “buy” rating to a “hold” rating in a research report on Wednesday, August 8th. Seven investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Humana currently has an average rating of “Buy” and a consensus target price of $339.79.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.
See Also: What is the 52-week high/low?
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.